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CORRESPONDENCE
Cephalosporinase induction and cephalosporin
resistance: a longstanding misinterpretation
For more than 20 years, and until very recently, it
has been suggested that ‘all Enterobacter spp.,
Citrobacter freundii, Serratia spp., Providencia spp.
and Morganella morganii should be reported resis-
tant to all third-generation cephalosporins’, with
the exception of urinary tract infection isolates [1].
The alleged reason is that these ampC-inducible
species yield ‘derepressed’ mutants, producing
high levels of AmpC b-lactamase which are
responsible for clinical failure. Other authors have
recommended screening for the inducible AmpC
b-lactamase and reporting as resistant only those
strains giving a positive result.
The aim of this letter is to analyze the genetic
background, the in vitro results, and the clinical
data supporting such an approach.
Confusion between induction and selection of
resistant mutants is aggravated by the very com-
monmisuseof theword ‘induction’ in the literature.
Induction of the AmpC chromosomal b-lacta-
mase: virtually all the above-mentioned bacteria
(but also Pseudomonas aeruginosa and other non-
fermentative Gram-negative bacteria) possess an
inducible b-lactamase with high afﬁnity for cepha-
losporins, produced at low levels [2–4]. It is a
characteristic trait of these bacterial species; there-
fore, reports that more than 20% of Enterobacter
and Morganella, and more than 60% of Serratia
strains are, not inducible can only be due to inade-
quate testing methods or misidentiﬁcation [5].
In the presence of a b-lactam which interacts
with the penicillin-binding proteins (PBPs) of the
bacteria, the resulting increase in peptidoglycan
precursors will trigger the activity of AmpG, a
permease which acts as a transmembrane signal
transducer. AmpG will overcome the joint control
of ampD and ampE and promote the conversion of
the repressed ampR into an activated form (inacti-
vation or loss of ampE or ampG results in a total
absence of induction). The activated ampR will
stimulate the expression of ampC, producing large
amounts of the AmpC chromosomal b-lactamase.
However, as soon as the inducer is removed, ampC
expression will return to normal.
b-Lactams can be divided into four categories on
the basis of their induction potential and their
stability in the presence of increased amounts of
b-lactamase produced.
(1) Inducer and unstable: aminopenicillins, ﬁrst-
generation cephalosporins, cephoxitin, cephot-
etan, and also clavulanic acid. These antibiotics
are rapidly inactivated by the increased b-lac-
tamase induced.
(2) Inducer but stable: one example is imipenem,
which remains active as long as another mech-
anism of resistance (decreased permeability) is
not associated.
(3) Non-inducer and limited stability: this is the
case for carboxy-ureidopenicillins, third-gen-
eration cephalosporins and aztreonam. These
antibiotics are active against inducible bacteria
in the absence of another inducer b-lactam.
(4) Non-inducer and relatively stable, such as
cefpirome and cefepime, these antibiotics do
not have the stability of imipenem and their
activity is affected in case of stable overpro-
duction resulting from mutation.
The major consequence of induction is the wild-
type pattern of the involved species towards
b-lactam antibiotics, i.e. resistance to aminopeni-
cillins (alone or combined with clavulanate or
sulbactam), ﬁrst-generation cephalosporins and
sensitivity to carboxy- and ureidopenicillins, third-
generation cephalosporins, aztreonam, cefepime,
cefpirome and imipenem.
Induction is an in vitro phenomenon with no
clinical impact; the only risk would be the very
unlikely combination of a strong inducer such as
cefoxitin with a third-generation cephalosporin.
Selection of resistant mutants (‘derepression’):
in contrast to induction, which is a transient phe-
nomenon, selection of resistant mutants producing
very high levels of b-lactamase has been observed
in vitro and in vivo [1,4,6–10].
These mutants, observed with a frequency of
106108 of wild-type bacterial cells, are resistant
to third-generation cephalosporins and aztreonam,
with minimum inhibitory concentrations (MICs)
of 32–256mg/L and usually also to carboxy- and
ureidopenicillins. All active b-lactams, except imi-
penem, can select such resistant mutants, but the
less stable, poor inducer compounds are the best
selectors. Indeed, for these compounds there is
a high increase in MICs observed between the
wild-type and the derepressed mutants which
often spans the antibiotic concentration, resulting
in killing the former and selecting the latter.
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The selection of resistant mutants is antibiotic-,
inoculum- and concentration-dependent and also
species- and strain-dependent. The frequency of
selection of resistant mutants is lower in Serratia
than in Enterobacter; in addition, the MICs attained
are much lower, especially with ceftazidime: in
one study, the MICs were 256 and 64 mg/mL for
cefotaxime and ceftazidime, respectively, in E.
cloacae, versus 8 and 1 mg/mL, respectively, in
Serratia [4]. This example indicates that not all
bacteria and antibiotics have the same level of risk.
From a genetic point of view, induction and the
selection of resistant mutants follow different
pathways. The resistant mutant pre-exists in the
susceptible bacterial population; it is neither
‘induced’ nor obtained by a mutagenic effect of
the antibiotic. It essentially involves a modiﬁcation
of the ampD gene, which can no longer repress
ampR, resulting in stable stimulation of ampC.
Hence, the ability of an antibiotic to select resistant
mutants is unrelated to its ability to induce the
AmpC b-lactamase [2,3,7].
The so-called third-generation cephalosporins
have been successfully used during the last
25 years to treat a wide array of infections. These
antibiotics were considered as a major break-
through, extending the activity of cephalosporins
to all enterobacterial species and Pseudomonas,
together with very favorable pharmacokinetic
parameters and very low toxicity.
A number of failures have been reported, but
with a highly variable incidence [7–10]; the highest
incidence of emergence of resistance during ther-
apy (up to 20%), reported in reference [1], was
observed in severely ill patients with Enterobacter
bacteremia, but the ﬁgures were small (six out of
31 patients) [8]. Moreover, at least two of these
strains, with MICs of 8 mg/mL, were clearly not
(fully) susceptible and the patients should have
been treated with other antibiotics.
Resistance to cephalosporins is selected step-
wise and involves various mechanisms (not only
‘derepression’). Low-level resistant mutants (often
due to decreased permeability) are more likely to
mutate to a higher level of resistance; it is the role of
the clinical microbiologist to recognize such strains
and inform the clinician that, despite the classiﬁca-
tion of the strain as ‘susceptible’ (by theNCCLS but
not by the BSAC or the French Antibiogram Com-
mittee), there is an increased risk of clinical failure.
In several other studies, the rate of clinical
failure was lower than the incidence of resis-
tant mutant selection (6% versus 28% in one study
[7] and 5.2% versus 9.9% in another study [10]).
In a study involving 392 patients, selection of
resistant mutants occurred in 6.1% of patients
infected by ‘inducible’ bacteria and treated with
third-generation cephalosporins or aztreonam.
The failure rate was 8.4% for Enterobacter spp.,
5% for Citrobacter, 4.8% for Serratia and 0% for
Morganella and Providencia. More unexpected in
this study was the emergence of resistance in bac-
teremicpatients:noneof the305patients treated [9].
A higher failure rate is reported in a very recent
paper, but the MICs against the susceptible and
resistant isolates are not reported [11].
Administration of another antibiotic (an amino-
glycoside or ﬂuoroquinolone) may decrease, but
not totally eliminate, the emergence of resistant
strains, probably owing to differences in their
pharmacokinetics [8].
Emergence of resistance to third-generation
cephalosporins in Enterobacter, C. freundii and
Serratia has to be compared to the emergence of
resistance to other antibiotics such as aminoglyco-
sides and ﬂuoroquinolones. In one review, resis-
tant strains emerged in 9.9% of patients treated
with cephalosporins, 5.9% of patients treated with
ciproﬂoxacin and 13.8% of patients treated with
aminoglycosides for infections due to the above-
mentioned bacteria [10].
In the same study, P. aeruginosa resistance deve-
loped in24.5%ofpatients treatedwith ciproﬂoxacin
and21.1%ofpatients treatedwithaminoglycosides.
In other studies, P. aeruginosa resistance emer-
ged in 16.9% of patients treated with aminoglyco-
sides [12] and 29.7% [12] to 34.7% [9] of patients
treated with imipenem.
Selection of resistant mutants during treatment
is a serious event, but is offset by the overall cure
rates and by the advantages of using third-gen-
eration cephalosporins, and must also be consid-
ered in the light of the therapeutic alternatives. The
ideal compound does not exist cefepime and, to a
lesser extent cefpirome, have a much lower pro-
pensity to select resistant mutants, but it can hap-
pen [6,13].
In an excellent in vitro study, resistance to cefe-
pime and cefpirome was easily selected in E.
cloacae after only one or two steps, with MICs
up to 32 and 128 mg/mL, respectively [6].
Moreover, these antibiotics readily select
mutants with altered permeability (80% of clones
versus 10% selected with ceftriaxone or ceftazi-
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dime) [6]. These clones are resistant not only to the
selecting agent but also to unrelated antibiotics
such as tetracyclines, chloramphenicol, trimetho-
prim and especially ﬂuoroquinolones, curtailing
the use of such compounds.
These antibiotics may also select resistant Kleb-
siella oxytoca (mutation of the chromosomal b-lac-
tamase) or Escherichia coli harboring plasmid-
mediated b-lactamases such as Oxa-1, which affect
cefepime more than ceftazidime. Cefepime and
cefpirome are recommended for nosocomial bac-
teremia and pneumonia (particularly in intensive
care units where Enterobacter spp. represent a sig-
niﬁcant risk), but should not replace third-genera-
tion cephalosporins for other infections.
Imipenem is clearly less active, more toxic and
more difﬁcult to administer; selection of resistance
may occur in the same species through different
mechanisms, curtailing the future use of other b-
lactams.
A ﬁnal factor which has to be taken into account
is the cost of other antibiotics in comparison to
third-generation cephalosporins.
The suggestion that all enterobacterial species
harbouring an inducible AmpC b-lactamase
should be considered as resistant to third-genera-
tion cephalosporins is neither accurate nor realis-
tic. Alarming data from a single study of
Enterobacter spp. are not very helpful; the clinician
needs more objective information on the advan-
tages and risks of using third-generation cepha-
losporins or alternatives.
A last point: if enterobacteria with inducible
cephalosporinase were considered as resistant to
third-generation cephalosporins, we should also
consider, based on similar observations of poten-
tial selection of resistant mutants, that all P. aeru-
ginosa are resistant to ceftazidime and all
Mycobacterium tuberculosis are resistant to strepto-
mycin, isoniazid, rifamycin, or ﬂuoroquinolones –
which is a nonsense.
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